Publications by authors named "Monica Restrepo"
Article Synopsis
- Vemurafenib and dabrafenib are BRAF inhibitors that improve survival in melanoma patients but can lead to the development of cutaneous squamous cell carcinoma (cSCC) in about 22% of cases.
- The mechanism behind cSCC development involves drug-induced paradoxical ERK activation, which causes cell overgrowth.
- The study reveals that vemurafenib also suppresses a cell death pathway through its effect on off-target kinases like ZAK, leading to reduced JNK activity and ultimately contributing to cSCC, highlighting the complexity of BRAF inhibitor effects and potential for combination therapies.
